Although further studies are needed to decipher the precise mechanisms whereby p300-dependent regulation of Myb controls MDS pathogenesis, our study further implicates Myb as a promising target for therapy in MDS or AML patients (42). Here, EP300 is linked to myelodysplastic syndrome.